365 reports of this reaction
1.9% of all SALMETEROL XINAFOATE reports
#9 most reported adverse reaction
DIZZINESS is the #9 most commonly reported adverse reaction for SALMETEROL XINAFOATE, manufactured by GlaxoSmithKline LLC. There are 365 FDA adverse event reports linking SALMETEROL XINAFOATE to DIZZINESS. This represents approximately 1.9% of all 19,705 adverse event reports for this drug.
Patients taking SALMETEROL XINAFOATE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for SALMETEROL XINAFOATE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for SALMETEROL XINAFOATE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 365 FDA reports for SALMETEROL XINAFOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 1.9% of all adverse event reports for SALMETEROL XINAFOATE, making it a notable side effect.
If you experience dizziness while taking SALMETEROL XINAFOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.